FDA Approves CBD-THC Drug Epidiolex

FDA Approves CBD-THC Drug Epidiolex

Epidiolex has been granted “Orphan Drug” status by the Food and Drug Administration, setting the stage for Phase 2 clinical trials later this year.
Epidiolex has been granted “Orphan Drug” status by the Food and Drug Administration, setting the stage for Phase 2 clinical trials later this year.

Published in full on BeyondTHC.com.

GW Pharmaceuticals’ CBD plant extract Epidiolex has been granted “Orphan Drug” status by the Food and Drug Administration, setting the stage for Phase 2 clinical trials later this year. The Realm of Caring Foundation, a Colorado-based non-profit, is also making CBD-rich plant extracts available to the parents of pediatric epilepsy patients. And other entities have begun producing and distributing CBD medicaments. GW will not have a monopoly—but it will have the edge with physicians who would rather prescribe an FDA-approved medication than recommend an extract available at the local dispensary.

Here’s GW’s press release, datelined London, Feb. 28, 2014:

GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex® in the Treatment of Lennox-Gastaut Syndrome

GW Pharmaceuticals plc (AIM:GWP) (Nasdaq:GWPH) (“GW”) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex®, GW’s product candidate that contains plant-derived Cannabidiol (CBD) as its active ingredient, for use in treating children with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant.

Read full article

This article was reprinted by Project CBD with permission. It may not be reproduced in any form without approval from the source.

Revision date: 
3月 3, 2014

本サイトの内容は、アメリカの非営利団体 Project CBD の記事を翻訳したものです。科学的エビデンスに基づいた情報の提供が目的であり、日本国内における違法行為を推奨するものではありません。 サイトのポリシーについてはこちらをご覧ください。

Thanks to our sponsors and supporters:

最新の記事

国連が大麻の医療効果を認める一方で、ヨーロッパは CBD の規制に頭を抱えています。

アクセスの多い疾患

CBDが効く可能性のある疾患のリストを作るため、学術誌に掲載された、査読を経た何百本もの論文を精査しました。

カンナビス・カンバセーション

CBDと「アントラージュ効果」、そして微生物叢が健康に与える影響について、イーサン・ルッソ博士に伺います。
CBDオイルはこうして抽出・加工されます
CBD を豊富に含むオイルを、安全かつ効果的に抽出・製造するには

人気の投稿